-
Something wrong with this record ?
Mutation and methylation status of KIT and TP53 in canine cutaneous and subcutaneous mast cell tumours
M. Vozdova, S. Kubickova, P. Fictum, H. Cernohorska, J. Fröhlich, J. Rubes
Language English Country Great Britain
Document type Journal Article
Grant support
16-26655S
Grantová Agentura České Republiky
CEITEC 2020 (LQ1601)
Ministerstvo Školství, Mládeže a Tělovýchovy
RO 0518
Ministerstvo Zemědělství
PubMed
31574575
DOI
10.1111/vco.12543
Knihovny.cz E-resources
- MeSH
- Mastocytosis, Cutaneous genetics surgery veterinary MeSH
- Mutation MeSH
- Tumor Suppressor Protein p53 genetics MeSH
- Skin Neoplasms genetics surgery veterinary MeSH
- Dog Diseases genetics surgery MeSH
- Pilot Projects MeSH
- Survival MeSH
- Proto-Oncogene Proteins c-kit genetics MeSH
- Dogs MeSH
- Subcutaneous Tissue MeSH
- Animals MeSH
- Check Tag
- Dogs MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Cutaneous and subcutaneous mast cell tumours (MCTs) are counted among the most frequent cancers in dogs. However, the genetic aetiology of their development is still mostly unknown, with the exception of KIT and tumor protein p53 (TP53 ) mutations reported in less than a half of cutaneous MCTs. In subcutaneous MCTs, no gene alterations were previously detected. We analysed KIT and TP53 mutations in cutaneous and subcutaneous MCTs, and identified methylated CpG sites in KIT and TP53 promoters and adjacent exon 1 regions. The mutation analysis focused on KIT exons 8, 9 and 11, and TP53 exons 5-8, and revealed mutations in 26% and 7% cutaneous MCT cases, respectively. Moreover, we report a first case of KIT mutation ever detected in subcutaneous MCTs. KIT exon 11 mutations and high Kiupel and Patnaik grades were associated with reduced survival in this study. Both KIT and TP53 gene were generally unmethylated in canine cutaneous MCTs. A sporadic methylation of the CpG positions in KIT promoter and adjacent exon 1 was detected in 70.4% of cutaneous and 82% of subcutaneous MCTs. A sporadic methylation of the CpG positions in the TP53 promoter and exon 1 was observed in 36.8% of the analysed cutaneous MCT samples. Only in two subcutaneous MCTs, we observed more than 30% of clones showing KIT methylation at the CpG positions 13 or 14. The CpG position 14 is involved in a predicted binding site for Sp1 transcription factor. However, the significance of KIT promoter methylation at this specific position needs further evaluation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026610
- 003
- CZ-PrNML
- 005
- 20211026132749.0
- 007
- ta
- 008
- 211013s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/vco.12543 $2 doi
- 035 __
- $a (PubMed)31574575
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vozdova, Miluse $u Department of Genetics and Reproduction, Central European Institute of Technology-Veterinary Research Institute, Brno, Czech Republic
- 245 10
- $a Mutation and methylation status of KIT and TP53 in canine cutaneous and subcutaneous mast cell tumours / $c M. Vozdova, S. Kubickova, P. Fictum, H. Cernohorska, J. Fröhlich, J. Rubes
- 520 9_
- $a Cutaneous and subcutaneous mast cell tumours (MCTs) are counted among the most frequent cancers in dogs. However, the genetic aetiology of their development is still mostly unknown, with the exception of KIT and tumor protein p53 (TP53 ) mutations reported in less than a half of cutaneous MCTs. In subcutaneous MCTs, no gene alterations were previously detected. We analysed KIT and TP53 mutations in cutaneous and subcutaneous MCTs, and identified methylated CpG sites in KIT and TP53 promoters and adjacent exon 1 regions. The mutation analysis focused on KIT exons 8, 9 and 11, and TP53 exons 5-8, and revealed mutations in 26% and 7% cutaneous MCT cases, respectively. Moreover, we report a first case of KIT mutation ever detected in subcutaneous MCTs. KIT exon 11 mutations and high Kiupel and Patnaik grades were associated with reduced survival in this study. Both KIT and TP53 gene were generally unmethylated in canine cutaneous MCTs. A sporadic methylation of the CpG positions in KIT promoter and adjacent exon 1 was detected in 70.4% of cutaneous and 82% of subcutaneous MCTs. A sporadic methylation of the CpG positions in the TP53 promoter and exon 1 was observed in 36.8% of the analysed cutaneous MCT samples. Only in two subcutaneous MCTs, we observed more than 30% of clones showing KIT methylation at the CpG positions 13 or 14. The CpG position 14 is involved in a predicted binding site for Sp1 transcription factor. However, the significance of KIT promoter methylation at this specific position needs further evaluation.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nemoci psů $x genetika $x chirurgie $7 D004283
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a kožní mastocytóza $x genetika $x chirurgie $x veterinární $7 D034701
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a protoonkogenní proteiny c-kit $x genetika $7 D019009
- 650 _2
- $a nádory kůže $x genetika $x chirurgie $x veterinární $7 D012878
- 650 _2
- $a subkutánní tkáň $7 D040521
- 650 _2
- $a přežití $7 D013534
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kubickova, Svatava $u Department of Genetics and Reproduction, Central European Institute of Technology-Veterinary Research Institute, Brno, Czech Republic
- 700 1_
- $a Fictum, Petr $u Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic
- 700 1_
- $a Cernohorska, Halina $u Department of Genetics and Reproduction, Central European Institute of Technology-Veterinary Research Institute, Brno, Czech Republic
- 700 1_
- $a Fröhlich, Jan $u Department of Genetics and Reproduction, Central European Institute of Technology-Veterinary Research Institute, Brno, Czech Republic
- 700 1_
- $a Rubes, Jiri $u Department of Genetics and Reproduction, Central European Institute of Technology-Veterinary Research Institute, Brno, Czech Republic
- 773 0_
- $w MED00007703 $t Veterinary and comparative oncology $x 1476-5829 $g Roč. 18, č. 3 (2020), s. 438-444
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31574575 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132755 $b ABA008
- 999 __
- $a ok $b bmc $g 1715366 $s 1147117
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 18 $c 3 $d 438-444 $e 20191106 $i 1476-5829 $m Veterinary and comparative oncology $n Vet Comp Oncol $x MED00007703
- GRA __
- $a 16-26655S $p Grantová Agentura České Republiky
- GRA __
- $a CEITEC 2020 (LQ1601) $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a RO 0518 $p Ministerstvo Zemědělství
- LZP __
- $a Pubmed-20211013